Huron Consulting Group reports Q1 results on May 8 with one clear story: short sellers have been unwinding steadily, leaving the stock's positioning far less adversarial than it was just weeks ago.
Short interest has fallen sharply over the past month — down roughly 25% — to 4.1% of the free float. That unwinding was most pronounced in early April, when estimated short shares ran above 850,000 before retreating to 657,000. Borrow conditions reflect that shift: the cost to borrow is an unremarkable 0.44%, and availability remains ample, suggesting no meaningful constraint on either side of the lending market. The ORTEX short score of 38.9 — in the lower half of the range — reinforces that this is not a crowded short setup.
Options positioning has nudged more cautious into the print. The put/call ratio rose to 0.84 on Tuesday — about 1.4 standard deviations above its 20-day average of 0.77 — signalling a modest tilt toward downside protection relative to recent norms. That said, the move is measured, not extreme, and the 52-week high for the PCR is a distant 16.5, which frames Tuesday's reading as a gentle hedge rather than a directional bet. The stock itself is flat to slightly higher over the past month, closing at $132.22, up about 2.1% on the week.
The analyst debate is the more interesting tension. The mean price target from the most recent consensus is $205.50 — implying roughly 55% upside from the current level. Coverage has been uniformly constructive, with Wedbush assuming coverage on April 9 at Outperform with a $160 target, and earlier raises from Barrington Research and Benchmark pushing targets well above $200. Bulls point to the Healthcare segment's 12% organic growth and double-digit expansion in digital transformation services. Bears flag the offset: strategy, innovation, and distressed advisory practices declined, and the first quarter typically carries the heaviest wage and compensation headwinds, which compress EBITDA margins before the year matures. Forward EPS momentum sits in the 84th percentile year-on-year, offering some support for the constructive view — but the gap between the current price and consensus targets may partly reflect valuation caution rather than conviction.
One institutional note adds texture. Fiduciary Management established a fresh position of over 524,000 shares as of year-end 2025, and Principal Global raised its stake by more than 163,000 shares in the March quarter. Meanwhile, the cluster of insider sales at the end of February — CEO, CFO, and COO all selling at $141, well above the current price — may attract attention given where the stock trades today.
The May 8 print is therefore a test of whether organic growth in Healthcare and the digital practice can hold its momentum despite sector disruption, and whether margins land in line with the company's own guidance range of $1.58–$1.66 billion RBR.
See the live data behind this article on ORTEX.
Open HURN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
